Advertisement

Antidiabetic Drugs

  • Daniel C. Howey
Chapter

Abstract

The safe and cost-effective development of new drugs has never been more dependent on well-designed early studies. There are a large number of potential sites of drug action and there are no templates for early phase human drug trials in diabetes. Thus, success will demand an understanding of the disease, its pathophysiology and the tools available to study it. As always, studies in normal volunteers will be crucial to the design and safe conduct of clinical trials. However, if the pharmacology of new drugs is directed at specific abnormalities, the expected pharmacology may not be manifest in normal people. Therefore, early studies of drug action in patients with diabetes will be of great importance to clinical trials design and product decision-making.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abernethy, D. R. and Greenblatt, D. J. (1986). Drug disposition in obese humans. An update. Clinical Pharmacokinetics, 11, 199–213CrossRefPubMedGoogle Scholar
  2. Ader, M. and Bergman, R. N. (1987). Insulin sensitivity in the intact organism. Baillière’s Clinical Endocrinology and Metabolism, Vol. 1. Ballière Tindall, pp. 879–910Google Scholar
  3. Andres, R., Swerdloff, L., Pozefsky, D. and Coleman, D. (1966). Manual feedback technique for the control of blood glucose concentration. In Skeggs, L. T. (Ed.), Automation in Analytical Chemistry, Technician Symposia 1965. Mediad Incorporated, New York, pp. 486–91Google Scholar
  4. Bagdade, J. D., Bierman, E. L. and Porte, D. (1967). The significance of basal insulin levels in the evaluation of the insulin response to glucose in diabetic and nondiabetic subjects. Journal of Clinical Investigation, 46, 1549–57PubMedCentralCrossRefPubMedGoogle Scholar
  5. Beard, J. C., Bergman, R. N., Ward, W. K. and Porte, D. (1986). The insulin sensitivity index in nondiabetic man: correlation between clamp-derived and IVGTT-derived values. Diabetes, 35, 362–9CrossRefPubMedGoogle Scholar
  6. Bergman, R. N., Finegood, D. T. and Ader, M. (1985). Assessment of insulin sensitivity in vivo. Endocrine Reviews, 6, 45–86CrossRefPubMedGoogle Scholar
  7. Bergman, R. N., Prager, R., Volund, A. and Olefsky, J. (1987). Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. Journal of Clinical Investigation, 79, 790–800PubMedCentralCrossRefPubMedGoogle Scholar
  8. Bloudin, R. A., Kolpek, J. H. and Mann, H. J. (1987). Influence of obesity on drug disposition. Clinical Pharmacy, 6, 706–14Google Scholar
  9. Brange, J., Ribel, U., Hansen, J. F., Dodson, G., Hansen, H. T., Havelund, S., Melberg, S. G., Norris, F., Norris, K., Snael, L., Sorensen, A. R. and Voigt, H. O. (1988). Monomeric insulins obtained by protein engineering and their medical implications. Nature, 333, 679–82CrossRefPubMedGoogle Scholar
  10. Brownlee, M., Cerami, A. and Vlassara, H. (1988). Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease. Diabetes/Metabolism Reviews, 4, 437–51CrossRefPubMedGoogle Scholar
  11. Canadian-European Randomized Control Trial Group (1988). Cyclosporin-induced remission of IDDM after early intervention. Diabetes, 37, 1574–82CrossRefGoogle Scholar
  12. Cohen, D. J., Loertscher, R., Rubin, M. F., Tilney, N. L., Carpenter, C. B. and Strom, T. B. (1984). Cyclosporin: a new immunosuppressive agent for organ transplantation. Annals of Internal Medicine, 101, 667–82CrossRefPubMedGoogle Scholar
  13. Faber, O. K. and Binder, C. (1986). C-peptide: an index of insulin secretion. Diabetes/Metabolism Reviews, 2, 331–45CrossRefPubMedGoogle Scholar
  14. Feldman, M. and Schiller, L. R. (1983). Disorders of gastrointestinal motility associated with diabetes mellitus. Annals of Internal Medicine, 98, 378–84CrossRefPubMedGoogle Scholar
  15. Ferrannini, E. (1988). The theoretical bases of indirect calorimetry: a review. Metabolism, 37, 287–301CrossRefPubMedGoogle Scholar
  16. Finegood, D. T., Bergman, R. N. and Vranic, M. (1988). Modeling error and apparent isotope discrimination confound estimation or endogenous glucose production during euglycemic glucose clamps. Diabetes, 37, 1025–34CrossRefPubMedGoogle Scholar
  17. Fraser, C. (1986). Analytical goals for glucose analyses. Annals of Clinical Biochemistry, 23, 379–89CrossRefPubMedGoogle Scholar
  18. Gerich, J. E. (1988). Glucose counterregulation and its impact on diabetes mellitus. Diabetes, 37, 1608–17CrossRefPubMedGoogle Scholar
  19. Greene, D. A., Lattimer, S. A. and Sima, A. A. F. (1988). Pathogenesis and prevention of diabetic neuropathy. Diabetes/Metabolism Reviews, 4, 201–21CrossRefPubMedGoogle Scholar
  20. Greenfield, M. S., Doberne, L., Kraemer, T. and Reaven, G. (1981). Assessment of insulin resistance with the insulin suppression test and the euglycemic clamp. Diabetes, 30, 387–92CrossRefPubMedGoogle Scholar
  21. Harano, Y., Hidaka, H., Takatsuki, K., Ohgaku, S., Haneda, M., Motoi, S., Kawgoe, K., Shigeta, Y. and Abe, H. (1978). Glucose, insulin and somatostatin infusion for the determination of insulin sensitivity in vivo. Metabolism, 27, 1449–52CrossRefPubMedGoogle Scholar
  22. Hetenyi, G., Perez, G. and Vranic, M. (1983). Turnover and precursor-product relationships of nonlipid metabolites. Physiological Reviews, 63, 606–67PubMedGoogle Scholar
  23. Himsworth, H. P. (1936). Diabetes mellitus. Its differentiation into insulin-sensitive and insulin-insensitive types. Lancet, 1, 127–30CrossRefGoogle Scholar
  24. Himsworth, H. P. and Kerr, R. B. (1939). Insulin-sensitive and insulin-insensitive types of diabetes mellitus. Clinical Science, 4, 119–52Google Scholar
  25. Isacson, D. and Stålhammar, J. (1987). Prescription drug use among diabetics—a population study. Journal of Chronic Diseases, 49, 651–60CrossRefGoogle Scholar
  26. Kinoshita, J. H. and Nishimura, C. (1988). The involvement of aldose reductase in diabetes complications. Diabetes/Metabolism Reviews, 4, 323–38CrossRefPubMedGoogle Scholar
  27. Lampman, R. M., Santinga, J. T., Bassett, D. R. and Savage, P. J. (1981). Cardiac arrhythmias during epinephrine-propranolol infusions for measurement of in vivo insulin resistance. Diabetes, 30, 618–20CrossRefPubMedGoogle Scholar
  28. Larson, E. R., Lipinski, C. A. and Sarges, R. (1988). Medicinal chemistry of aldose reductase inhibitors. Medicinal Research Reviews, 8, 159–86CrossRefPubMedGoogle Scholar
  29. Lebovitz, H. E. and Feinglos, M. N. (1983). The oral hypoglycemic agents. In Ellenberg, M. and Rifkin, H. (Eds.), Diabetes Mellitus: Theory and Practice. Medical Examination Publishing Company, New Hyde Park, pp. 591–609Google Scholar
  30. Markussen, J., Hougaard, P., Ribel, U., Sorensen, A. R. and Sorensen, E. (1987). Soluble prolonged-acting insulin derivatives. I. Degree of protraction and crystallizability of insulins substituted in the termini of the B-chain. Protein Engineering, 1, 205–13CrossRefPubMedGoogle Scholar
  31. Mazze, R. S., Shamoon, H., Pasmantier, R., Lucido, D., Murphy, J., Hartmenn, K., Kuykendall, V. and Lopatin, W. (1984). Reliability of blood glucose monitoring by patients with diabetes mellitus. American Journal of Medicine, 77, 211–17CrossRefPubMedGoogle Scholar
  32. Meistas, M. T., Zadik, Z., Margolis, S. and Kowarski, A. A. (1981). Correlation of urinary excretion of C-peptide with the integrated concentration and secretion rate of insulin. Diabetes, 30, 639–43CrossRefPubMedGoogle Scholar
  33. Melani, F., Lawecki, J., Bartelt, K. M. and Pfeiffer, E. F. (1967). Serum insulin levels in subjects with normal metabolism, obese patients and diabetics after intravenous administration of glucose, tolbutamide and glucagon. Diabetologia, 3, 422–6CrossRefPubMedGoogle Scholar
  34. Mohrbacher, R. J., Kiorpes, T. C. and Bowden, C. R. (1987). Pharmacologic intervention in diabetes mellitus. Annual Reports in Medicinal Chemistry, 22, 213–22CrossRefGoogle Scholar
  35. Morgensen, C. E., Schmitz, A. and Christensen, C. K. (1988). Comparative renal physiology relevant to IDDM and NIDDM patients. Diabetes/Metabolism Reviews, 4, 453–83CrossRefGoogle Scholar
  36. National Diabetes Data Group (1979). Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes, 28, 1039–57CrossRefGoogle Scholar
  37. Nattrass, M. and Dodds, K. E. (1987). Interpretation of radioreceptor assays. Annals of Clinical Biochemistry, 24, 13–21CrossRefPubMedGoogle Scholar
  38. Peacock, I. (1984). Glycosylated haemoglobin: measurement and clinical use. Journal of Clinical Pathology, 37, 841–51PubMedCentralCrossRefPubMedGoogle Scholar
  39. Pohl, S. L., Gonder-Frederick, L., Cox, D. J. and Evans, W. S. (1985). Self-measurement of blood glucose concentration: clinical significance of patient-generated measurements. Diabetes Care, 8, 617–19CrossRefPubMedGoogle Scholar
  40. Polonsky, K. S. and Rubenstein, A. H. (1986). Current approaches to measurement of insulin secretion. Diabetes/Metabolism Reviews, 2, 315–29CrossRefPubMedGoogle Scholar
  41. Radziuk, J. and Lickley, H. L. A. (1985). The metabolic clearance of glucose: measurement and meaning. Diabetologia, 28, 315–22CrossRefPubMedGoogle Scholar
  42. Rendel, M., Lassek, W. D., Ross, D. A., Smith, C., Kernek, S., Williams, J., Brown, M., Willingmyre, L. and Yamamoto, L. (1983). A pharmaceutical profile of diabetic patients. Journal of Chronic Diseases, 36, 193–202CrossRefGoogle Scholar
  43. Rendel, M., Rasbold, K., Nierenberg, J., Krohn, R., Hermanson, G., Klenk, D. and Smith, P. K. (1986). Comparison and contrast of affinity chromatographic determinations of plasma glycated albumin and total glycated plasma protein. Clinical Biochemistry, 19, 216–20CrossRefGoogle Scholar
  44. Rizza, R. A., Mandarino, L. J. and Gerich, J. E. (1981). Mechanisms of insulin resistance in man: assessment using insulin dose-response curve in conjunction with insulin-receptor binding. The American Journal of Medicine, 70, 169–76CrossRefPubMedGoogle Scholar
  45. Ruiz-Cabello, F. and Erill, S. (1984). Abnormal serum protein binding of acidic drugs in diabetes mellitus. Clinical Pharmacology and Therapeutics, 36, 691–5CrossRefPubMedGoogle Scholar
  46. Service, F. J., O’Brien, P. C. and Rizza, R. A. (1987). Measures of glucose control. Diabetes Care, 10, 225–37CrossRefPubMedGoogle Scholar
  47. Shamoon, H., Mazze, R., Pasmantier, R., Lucido, D. and Murphy, J. A. (1986). Assessment of long-term glycemia in type I diabetes using multiple blood glucose values stored in a memory-containing reflectometer. American Journal of Medicine, 80, 1086–92CrossRefPubMedGoogle Scholar
  48. Shen, S. W., Reaven, G. M. and Farquhar, J. W. (1970). Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. Journal of Clinical Investigation, 49, 2151–60PubMedCentralCrossRefPubMedGoogle Scholar
  49. Siesjö, B. K. (1988). Hypoglycemia, brain metabolism, and brain damage. Diabetes/Metabolism Reviews, 4, 113–44CrossRefPubMedGoogle Scholar
  50. Skyler, J. S. (1987). Immune intervention studies in insulin-dependent diabetes mellitus. Diabetes/Metabolism Reviews, 4, 1017–35CrossRefGoogle Scholar
  51. Tsuchiya, S., Sakurai, T. and Sekiguchi, S. (1984). Nonenzymatic glycosylation of human serum albumin and its influence on binding capacity of sulfonylureas. Biochemical Pharmacology, 33, 2967–71CrossRefPubMedGoogle Scholar
  52. Verdonk, C. A., Rizza, R., Westland, R. E., Nelson, R. L., Gerich, J. E. and Service, F. J. (1980). Glucose clamping using the Biostator GCIIS. Hormone and Metabolic Research, 12, 133–5CrossRefPubMedGoogle Scholar
  53. World Health Organization Study Group (1985). Diabetes Mellitus. Technical Report Series No. 727, GenevaGoogle Scholar
  54. Zavaroni, I., Deferrari, G., Lugari, R., Bonora, E., Garibotto, G., Dall’aglio, E., Robaudo, C. and Gnudi, A. (1987). Renal metabolism of C-peptide in man. Journal of Clinical Endocrinology and Metabolism, 65, 494–8CrossRefPubMedGoogle Scholar
  55. Zysset, T. and Wietholtz, H. (1988). Differential effect of type I and type II diabetes on antipyrine disposition in man. European Journal of Clinical Pharmacology, 34, 369–75CrossRefPubMedGoogle Scholar

Copyright information

© The editors and contributors 1990

Authors and Affiliations

  • Daniel C. Howey
    • 1
  1. 1.William N. Wishard Memorial HospitalEli Lilly and CompanyIndianapolisUSA

Personalised recommendations